The US Melatonin market ended June 2026 with stable weekly pricing despite recording a slight monthly decline. Early June was supported by balanced supply-demand conditions and routine procurement from nutraceutical and OTC supplement manufacturers. During mid-June, buying activity softened temporarily as buyers relied on comfortable inventories, leading to a modest price correction of around 0.4%. However, demand improved by the final week, allowing Melatonin prices to stabilize and market sentiment to return to equilibrium. Supply fundamentals remained healthy throughout the month, with stable feedstock costs, uninterrupted manufacturing operations, and sufficient inventories ensuring consistent availability of Melatonin. No major production outages or logistics disruptions were reported, preventing significant market volatility. Although the 12-week moving average continued to indicate an underlying bearish trend, the latest weekly assessments reflected improving short-term market stability. Looking forward, analysts expect the Melatonin market to remain largely rangebound. Balanced inventories, stable production economics, and steady downstream demand are likely to keep Melatonin prices within a narrow range unless stronger seasonal consumption or unexpected supply-side disruptions create fresh momentum. Current market conditions suggest limited downside risk alongside restrained upside potential.
The Melatonin market in the United States concluded June 2026 on a stable footing despite registering a modest monthly decline. Melatonin prices remained unchanged during the final week of June, reflecting balanced supply-demand fundamentals after a brief softening earlier in the month. Early June witnessed stable trading conditions supported by consistent procurement from nutraceutical and over-the-counter supplement manufacturers, while mid-month buying activity slowed slightly, resulting in limited downward pressure. However, demand recovered toward the end of June, allowing the Melatonin market to regain equilibrium and maintain stable weekly pricing.
Demand for Melatonin followed a mixed pattern throughout June. Routine replenishment from dietary supplement manufacturers supported the market during the first half of the month, but procurement activity weakened briefly in mid-June as buyers adopted a cautious purchasing strategy amid sufficient inventories. By late June, inquiries improved, helping stabilize Melatonin prices. Despite this recovery, the broader market continued to reflect the impact of an ongoing correction, with the 12-week moving average remaining on a downward trajectory. This indicates that although short-term demand has steadied, Melatonin continues to experience mild bearish momentum compared to previous months.
Supply-side conditions remained favorable throughout June. Stable feedstock costs ensured that Melatonin production economics remained unchanged, preventing significant cost-driven price fluctuations. Manufacturers maintained steady operating rates while inventories remained sufficient to meet downstream requirements. No major production outages, maintenance shutdowns, or logistical disruptions affected availability during the month. Balanced inventory levels and uninterrupted production allowed the Melatonin supply chain to function smoothly, contributing to the calm market environment observed in late June.
Weekly price movements highlighted the market's stability. Early June recorded largely unchanged Melatonin prices before a modest decline of approximately 0.4% emerged during the middle of the month. This minor correction aligned with the broader multi-week bearish trend rather than reflecting any major deterioration in market fundamentals. By the final week of June, Melatonin prices stabilized once again as balanced purchasing and adequate supply restored market equilibrium. Overall, the monthly trend pointed to a controlled correction rather than a significant downturn.
Looking ahead, analysts expect the Melatonin market to remain rangebound during the coming weeks. Stable production costs, balanced inventories, and consistent downstream demand are expected to limit major price volatility. Unless stronger seasonal demand or unexpected feedstock cost increases emerge, Melatonin prices are likely to trade within a narrow range. Current market indicators suggest that downside risks remain limited, while any meaningful upward movement will depend on stronger purchasing activity from nutraceutical manufacturers and broader improvements in consumer demand.
